18 / 74 · 1:06 · Original AXON film
Dihexa
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Proposed mechanism
Dihexa is often discussed as a brain-research compound. Its proposed story centers on HGF and c-Met, a signaling system involved in how cells respond to growth signals. [1]
2014 paper retracted in 2025
There is an important update: a frequently cited 2014 paper connecting these effects to HGF and c-Met was retracted in 2025. [1] [2]
Retraction changes the evidence
That paper should not be presented as reliable proof that Dihexa builds useful brain connections or improves cognition. Cell and animal claims already require separate testing in people. [2]
Human efficacy and safety remain unestablished
FDA also notes missing human exposure data for Dihexa acetate. A plausible target is a starting point for research, not a demonstrated memory treatment. [3]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Benoist et al. (2014), now retracted: HGF/c-Met hypothesis →The proposed mechanism and the linked retraction; not evidence of efficacy.
- Journal retraction notice (2025) →Formal retraction of the 2014 paper.
- FDA peptide safety information: Dihexa acetate →No human exposure data identified for Dihexa acetate.
